nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—prostate cancer	0.26	0.679	CbGaD
Afatinib—EGFR—prostate cancer	0.123	0.321	CbGaD
Afatinib—EGFR—Docetaxel—prostate cancer	0.0648	0.214	CbGbCtD
Afatinib—ABCG2—Cabazitaxel—prostate cancer	0.0319	0.106	CbGbCtD
Afatinib—ABCG2—Estrone—prostate cancer	0.0312	0.103	CbGbCtD
Afatinib—ABCG2—Conjugated Estrogens—prostate cancer	0.0204	0.0675	CbGbCtD
Afatinib—ABCG2—Mitoxantrone—prostate cancer	0.0185	0.0614	CbGbCtD
Afatinib—ABCG2—Estradiol—prostate cancer	0.0179	0.0593	CbGbCtD
Afatinib—ABCB1—Estramustine—prostate cancer	0.0174	0.0577	CbGbCtD
Afatinib—ABCG2—Etoposide—prostate cancer	0.0117	0.0387	CbGbCtD
Afatinib—ABCB1—Cabazitaxel—prostate cancer	0.0115	0.0381	CbGbCtD
Afatinib—ABCB1—Estrone—prostate cancer	0.0112	0.0372	CbGbCtD
Afatinib—ABCG2—Docetaxel—prostate cancer	0.0107	0.0354	CbGbCtD
Afatinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.01	0.0332	CbGbCtD
Afatinib—ABCG2—Doxorubicin—prostate cancer	0.00797	0.0264	CbGbCtD
Afatinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00735	0.0243	CbGbCtD
Afatinib—ABCB1—Mitoxantrone—prostate cancer	0.00669	0.0221	CbGbCtD
Afatinib—ABCB1—Estradiol—prostate cancer	0.00646	0.0214	CbGbCtD
Afatinib—ABCB1—Prednisone—prostate cancer	0.00555	0.0184	CbGbCtD
Afatinib—ABCB1—Etoposide—prostate cancer	0.00422	0.014	CbGbCtD
Afatinib—ABCB1—Docetaxel—prostate cancer	0.00386	0.0128	CbGbCtD
Afatinib—ABCB1—Doxorubicin—prostate cancer	0.00288	0.00952	CbGbCtD
Afatinib—EPHA6—prostate gland—prostate cancer	0.00258	0.0541	CbGeAlD
Afatinib—PHKG2—prostate gland—prostate cancer	0.00249	0.0521	CbGeAlD
Afatinib—ERBB4—prostate gland—prostate cancer	0.00224	0.0469	CbGeAlD
Afatinib—ERBB2—prostate gland—prostate cancer	0.00224	0.0469	CbGeAlD
Afatinib—DYRK1A—prostate gland—prostate cancer	0.00215	0.0451	CbGeAlD
Afatinib—EGFR—prostate gland—prostate cancer	0.0019	0.0398	CbGeAlD
Afatinib—IRAK1—prostate gland—prostate cancer	0.00167	0.0351	CbGeAlD
Afatinib—ERBB2—epithelium—prostate cancer	0.00164	0.0345	CbGeAlD
Afatinib—ERBB4—epithelium—prostate cancer	0.00164	0.0345	CbGeAlD
Afatinib—LCK—prostate gland—prostate cancer	0.00163	0.0342	CbGeAlD
Afatinib—ERBB2—renal system—prostate cancer	0.00152	0.032	CbGeAlD
Afatinib—DYRK1A—renal system—prostate cancer	0.00147	0.0308	CbGeAlD
Afatinib—HIPK4—testis—prostate cancer	0.00144	0.0301	CbGeAlD
Afatinib—EPHA6—testis—prostate cancer	0.00114	0.0238	CbGeAlD
Afatinib—PHKG2—testis—prostate cancer	0.0011	0.023	CbGeAlD
Afatinib—LCK—urethra—prostate cancer	0.00109	0.0229	CbGeAlD
Afatinib—BLK—lymph node—prostate cancer	0.00104	0.0218	CbGeAlD
Afatinib—ERBB2—testis—prostate cancer	0.000985	0.0207	CbGeAlD
Afatinib—ERBB4—testis—prostate cancer	0.000985	0.0207	CbGeAlD
Afatinib—DYRK1A—testis—prostate cancer	0.000948	0.0199	CbGeAlD
Afatinib—ABL1—prostate gland—prostate cancer	0.000937	0.0196	CbGeAlD
Afatinib—IRAK1—bone marrow—prostate cancer	0.000862	0.0181	CbGeAlD
Afatinib—LCK—bone marrow—prostate cancer	0.00084	0.0176	CbGeAlD
Afatinib—EGFR—testis—prostate cancer	0.000835	0.0175	CbGeAlD
Afatinib—PHKG2—lymph node—prostate cancer	0.000794	0.0167	CbGeAlD
Afatinib—ABL1—seminal vesicle—prostate cancer	0.000792	0.0166	CbGeAlD
Afatinib—Vandetanib—BMPR1B—prostate cancer	0.000782	0.154	CrCbGaD
Afatinib—Vandetanib—IRAK4—prostate cancer	0.000782	0.154	CrCbGaD
Afatinib—Gefitinib—IRAK4—prostate cancer	0.000743	0.146	CrCbGaD
Afatinib—IRAK1—testis—prostate cancer	0.000737	0.0155	CbGeAlD
Afatinib—LCK—testis—prostate cancer	0.000718	0.0151	CbGeAlD
Afatinib—ERBB2—lymph node—prostate cancer	0.000714	0.015	CbGeAlD
Afatinib—DYRK1A—lymph node—prostate cancer	0.000687	0.0144	CbGeAlD
Afatinib—ABL1—renal system—prostate cancer	0.000638	0.0134	CbGeAlD
Afatinib—ABL1—urethra—prostate cancer	0.000627	0.0132	CbGeAlD
Afatinib—EGFR—lymph node—prostate cancer	0.000605	0.0127	CbGeAlD
Afatinib—ABCG2—prostate gland—prostate cancer	0.000591	0.0124	CbGeAlD
Afatinib—IRAK1—lymph node—prostate cancer	0.000534	0.0112	CbGeAlD
Afatinib—LCK—lymph node—prostate cancer	0.000521	0.0109	CbGeAlD
Afatinib—ABCG2—seminal vesicle—prostate cancer	0.0005	0.0105	CbGeAlD
Afatinib—ABL1—bone marrow—prostate cancer	0.000483	0.0101	CbGeAlD
Afatinib—ABL1—testis—prostate cancer	0.000413	0.00866	CbGeAlD
Afatinib—ABCG2—urethra—prostate cancer	0.000395	0.0083	CbGeAlD
Afatinib—Gefitinib—CHEK2—prostate cancer	0.000383	0.0754	CrCbGaD
Afatinib—ERBB2—Exemestane—Estrone—prostate cancer	0.000367	0.116	CbGdCrCtD
Afatinib—Vandetanib—ERBB3—prostate cancer	0.000359	0.0707	CrCbGaD
Afatinib—Gefitinib—ERBB3—prostate cancer	0.000341	0.0672	CrCbGaD
Afatinib—ERBB2—Exemestane—Conjugated Estrogens—prostate cancer	0.000323	0.102	CbGdCrCtD
Afatinib—ABCG2—bone marrow—prostate cancer	0.000304	0.00638	CbGeAlD
Afatinib—ABL1—lymph node—prostate cancer	0.000299	0.00627	CbGeAlD
Afatinib—Vandetanib—PDGFRB—prostate cancer	0.000297	0.0585	CrCbGaD
Afatinib—ABCB1—prostate gland—prostate cancer	0.000291	0.00611	CbGeAlD
Afatinib—ABCG2—testis—prostate cancer	0.00026	0.00546	CbGeAlD
Afatinib—ABCB1—seminal vesicle—prostate cancer	0.000246	0.00517	CbGeAlD
Afatinib—Vandetanib—SRC—prostate cancer	0.00024	0.0472	CrCbGaD
Afatinib—ERBB2—Podofilox—Etoposide—prostate cancer	0.000231	0.0732	CbGdCrCtD
Afatinib—Vandetanib—KDR—prostate cancer	0.000225	0.0443	CrCbGaD
Afatinib—ABCB1—epithelium—prostate cancer	0.000214	0.00449	CbGeAlD
Afatinib—ABCB1—renal system—prostate cancer	0.000199	0.00416	CbGeAlD
Afatinib—ABCB1—urethra—prostate cancer	0.000195	0.00409	CbGeAlD
Afatinib—Vandetanib—VEGFA—prostate cancer	0.000191	0.0376	CrCbGaD
Afatinib—ABCG2—lymph node—prostate cancer	0.000189	0.00396	CbGeAlD
Afatinib—ABL1—Levorphanol—Estrone—prostate cancer	0.000171	0.0541	CbGdCrCtD
Afatinib—Vandetanib—EGFR—prostate cancer	0.000161	0.0317	CrCbGaD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—prostate cancer	0.000157	0.0496	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—prostate cancer	0.000157	0.0496	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—prostate cancer	0.000157	0.0496	CbGdCrCtD
Afatinib—Gefitinib—EGFR—prostate cancer	0.000153	0.0301	CrCbGaD
Afatinib—ABCB1—bone marrow—prostate cancer	0.00015	0.00315	CbGeAlD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—prostate cancer	0.000145	0.0459	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—prostate cancer	0.000145	0.0459	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—prostate cancer	0.000145	0.0459	CbGdCrCtD
Afatinib—ABL1—Levorphanol—Estradiol—prostate cancer	0.000129	0.041	CbGdCrCtD
Afatinib—Gefitinib—CYP3A5—prostate cancer	0.000129	0.0254	CrCbGaD
Afatinib—ABCB1—testis—prostate cancer	0.000128	0.00269	CbGeAlD
Afatinib—ERBB2—Doxorubicin—Epirubicin—prostate cancer	0.00012	0.0382	CbGdCrCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—prostate cancer	0.000111	0.0353	CbGdCrCtD
Afatinib—ERBB2—Exemestane—Prednisone—prostate cancer	9.54e-05	0.0302	CbGdCrCtD
Afatinib—ABCB1—lymph node—prostate cancer	9.3e-05	0.00195	CbGeAlD
Afatinib—ABL1—Doxorubicin—Epirubicin—prostate cancer	8.99e-05	0.0285	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—prostate cancer	8.99e-05	0.0285	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—prostate cancer	8.99e-05	0.0285	CbGdCrCtD
Afatinib—Gefitinib—CYP2C19—prostate cancer	8.78e-05	0.0173	CrCbGaD
Afatinib—Gefitinib—CYP1A1—prostate cancer	8.75e-05	0.0172	CrCbGaD
Afatinib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	8.32e-05	0.0264	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—prostate cancer	8.32e-05	0.0264	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—prostate cancer	8.32e-05	0.0264	CbGdCrCtD
Afatinib—ERBB2—Levonorgestrel—Ethinyl Estradiol—prostate cancer	8.21e-05	0.026	CbGdCrCtD
Afatinib—Weight decreased—Prednisone—prostate cancer	8.12e-05	0.000674	CcSEcCtD
Afatinib—Dyspepsia—Estradiol—prostate cancer	8.09e-05	0.000672	CcSEcCtD
Afatinib—Decreased appetite—Estradiol—prostate cancer	7.99e-05	0.000663	CcSEcCtD
Afatinib—Urinary tract disorder—Capecitabine—prostate cancer	7.97e-05	0.000662	CcSEcCtD
Afatinib—Gastrointestinal disorder—Estradiol—prostate cancer	7.93e-05	0.000659	CcSEcCtD
Afatinib—Diarrhoea—Goserelin—prostate cancer	7.93e-05	0.000659	CcSEcCtD
Afatinib—Connective tissue disorder—Capecitabine—prostate cancer	7.93e-05	0.000658	CcSEcCtD
Afatinib—Fatigue—Estradiol—prostate cancer	7.92e-05	0.000658	CcSEcCtD
Afatinib—Urethral disorder—Capecitabine—prostate cancer	7.91e-05	0.000657	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—prostate cancer	7.9e-05	0.000656	CcSEcCtD
Afatinib—Constipation—Estradiol—prostate cancer	7.86e-05	0.000653	CcSEcCtD
Afatinib—Diarrhoea—Conjugated Estrogens—prostate cancer	7.86e-05	0.000652	CcSEcCtD
Afatinib—Eye disorder—Docetaxel—prostate cancer	7.79e-05	0.000647	CcSEcCtD
Afatinib—Dizziness—Goserelin—prostate cancer	7.67e-05	0.000637	CcSEcCtD
Afatinib—Dyspnoea—Mitoxantrone—prostate cancer	7.63e-05	0.000634	CcSEcCtD
Afatinib—Cough—Etoposide—prostate cancer	7.61e-05	0.000632	CcSEcCtD
Afatinib—Dizziness—Conjugated Estrogens—prostate cancer	7.59e-05	0.000631	CcSEcCtD
Afatinib—Dehydration—Epirubicin—prostate cancer	7.55e-05	0.000627	CcSEcCtD
Afatinib—Eye disorder—Capecitabine—prostate cancer	7.54e-05	0.000626	CcSEcCtD
Afatinib—Dyspepsia—Mitoxantrone—prostate cancer	7.54e-05	0.000626	CcSEcCtD
Afatinib—Mediastinal disorder—Docetaxel—prostate cancer	7.51e-05	0.000624	CcSEcCtD
Afatinib—Dry skin—Epirubicin—prostate cancer	7.45e-05	0.000618	CcSEcCtD
Afatinib—Decreased appetite—Mitoxantrone—prostate cancer	7.44e-05	0.000618	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—prostate cancer	7.39e-05	0.000614	CcSEcCtD
Afatinib—Fatigue—Mitoxantrone—prostate cancer	7.38e-05	0.000613	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	7.38e-05	0.000613	CcSEcCtD
Afatinib—Vomiting—Goserelin—prostate cancer	7.37e-05	0.000612	CcSEcCtD
Afatinib—Alopecia—Docetaxel—prostate cancer	7.36e-05	0.000611	CcSEcCtD
Afatinib—Constipation—Mitoxantrone—prostate cancer	7.32e-05	0.000608	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—prostate cancer	7.31e-05	0.000607	CcSEcCtD
Afatinib—Rash—Goserelin—prostate cancer	7.31e-05	0.000607	CcSEcCtD
Afatinib—Dermatitis—Goserelin—prostate cancer	7.3e-05	0.000606	CcSEcCtD
Afatinib—Vomiting—Conjugated Estrogens—prostate cancer	7.3e-05	0.000606	CcSEcCtD
Afatinib—Mental disorder—Docetaxel—prostate cancer	7.3e-05	0.000606	CcSEcCtD
Afatinib—Mediastinal disorder—Capecitabine—prostate cancer	7.27e-05	0.000604	CcSEcCtD
Afatinib—Body temperature increased—Estradiol—prostate cancer	7.26e-05	0.000603	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—prostate cancer	7.26e-05	0.000603	CcSEcCtD
Afatinib—Headache—Goserelin—prostate cancer	7.26e-05	0.000603	CcSEcCtD
Afatinib—Malnutrition—Docetaxel—prostate cancer	7.25e-05	0.000602	CcSEcCtD
Afatinib—Rash—Conjugated Estrogens—prostate cancer	7.24e-05	0.000601	CcSEcCtD
Afatinib—Dermatitis—Conjugated Estrogens—prostate cancer	7.23e-05	0.000601	CcSEcCtD
Afatinib—Headache—Conjugated Estrogens—prostate cancer	7.19e-05	0.000597	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—prostate cancer	7.16e-05	0.000595	CcSEcCtD
Afatinib—Alopecia—Capecitabine—prostate cancer	7.13e-05	0.000592	CcSEcCtD
Afatinib—Dysgeusia—Docetaxel—prostate cancer	7.1e-05	0.00059	CcSEcCtD
Afatinib—Infection—Etoposide—prostate cancer	7.08e-05	0.000588	CcSEcCtD
Afatinib—Mental disorder—Capecitabine—prostate cancer	7.07e-05	0.000587	CcSEcCtD
Afatinib—Connective tissue disorder—Prednisone—prostate cancer	7.06e-05	0.000586	CcSEcCtD
Afatinib—Malnutrition—Capecitabine—prostate cancer	7.02e-05	0.000583	CcSEcCtD
Afatinib—Back pain—Docetaxel—prostate cancer	7.01e-05	0.000583	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—prostate cancer	6.99e-05	0.00058	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—prostate cancer	6.97e-05	0.000579	CcSEcCtD
Afatinib—Skin disorder—Etoposide—prostate cancer	6.92e-05	0.000575	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—prostate cancer	6.89e-05	0.000572	CcSEcCtD
Afatinib—Nausea—Goserelin—prostate cancer	6.89e-05	0.000572	CcSEcCtD
Afatinib—Dysgeusia—Capecitabine—prostate cancer	6.88e-05	0.000571	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—prostate cancer	6.84e-05	0.000568	CcSEcCtD
Afatinib—Nausea—Conjugated Estrogens—prostate cancer	6.82e-05	0.000566	CcSEcCtD
Afatinib—Back pain—Capecitabine—prostate cancer	6.79e-05	0.000564	CcSEcCtD
Afatinib—Body temperature increased—Mitoxantrone—prostate cancer	6.77e-05	0.000562	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	6.77e-05	0.000562	CcSEcCtD
Afatinib—Muscle spasms—Capecitabine—prostate cancer	6.75e-05	0.000561	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—prostate cancer	6.72e-05	0.000558	CcSEcCtD
Afatinib—Eye disorder—Prednisone—prostate cancer	6.71e-05	0.000558	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—prostate cancer	6.63e-05	0.000551	CcSEcCtD
Afatinib—Asthenia—Estradiol—prostate cancer	6.59e-05	0.000548	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—prostate cancer	6.52e-05	0.000542	CcSEcCtD
Afatinib—Pruritus—Estradiol—prostate cancer	6.5e-05	0.00054	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—prostate cancer	6.35e-05	0.000528	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—prostate cancer	6.35e-05	0.000527	CcSEcCtD
Afatinib—Alopecia—Prednisone—prostate cancer	6.35e-05	0.000527	CcSEcCtD
Afatinib—Cough—Docetaxel—prostate cancer	6.33e-05	0.000526	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—prostate cancer	6.3e-05	0.000523	CcSEcCtD
Afatinib—Mental disorder—Prednisone—prostate cancer	6.29e-05	0.000523	CcSEcCtD
Afatinib—Diarrhoea—Estradiol—prostate cancer	6.29e-05	0.000522	CcSEcCtD
Afatinib—Infestation—Epirubicin—prostate cancer	6.26e-05	0.00052	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—prostate cancer	6.26e-05	0.00052	CcSEcCtD
Afatinib—Malnutrition—Prednisone—prostate cancer	6.25e-05	0.000519	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—prostate cancer	6.19e-05	0.000514	CcSEcCtD
Afatinib—Renal failure—Epirubicin—prostate cancer	6.15e-05	0.000511	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—prostate cancer	6.15e-05	0.000511	CcSEcCtD
Afatinib—Asthenia—Mitoxantrone—prostate cancer	6.14e-05	0.00051	CcSEcCtD
Afatinib—Fatigue—Etoposide—prostate cancer	6.14e-05	0.00051	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	6.13e-05	0.000509	CcSEcCtD
Afatinib—Cough—Capecitabine—prostate cancer	6.13e-05	0.000509	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—prostate cancer	6.1e-05	0.000507	CcSEcCtD
Afatinib—Constipation—Etoposide—prostate cancer	6.09e-05	0.000506	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—prostate cancer	6.08e-05	0.000505	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—prostate cancer	6.08e-05	0.000505	CcSEcCtD
Afatinib—Dizziness—Estradiol—prostate cancer	6.08e-05	0.000505	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—prostate cancer	6.04e-05	0.000501	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.94e-05	0.000493	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—prostate cancer	5.92e-05	0.000492	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—prostate cancer	5.9e-05	0.00049	CcSEcCtD
Afatinib—Infection—Docetaxel—prostate cancer	5.88e-05	0.000488	CcSEcCtD
Afatinib—Vandetanib—CYP3A4—prostate cancer	5.88e-05	0.0116	CrCbGaD
Afatinib—Weight decreased—Doxorubicin—prostate cancer	5.88e-05	0.000488	CcSEcCtD
Afatinib—Diarrhoea—Mitoxantrone—prostate cancer	5.86e-05	0.000487	CcSEcCtD
Afatinib—Vomiting—Estradiol—prostate cancer	5.84e-05	0.000485	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—prostate cancer	5.83e-05	0.000484	CcSEcCtD
Afatinib—Nervous system disorder—Docetaxel—prostate cancer	5.8e-05	0.000482	CcSEcCtD
Afatinib—Rash—Estradiol—prostate cancer	5.79e-05	0.000481	CcSEcCtD
Afatinib—Infestation—Doxorubicin—prostate cancer	5.79e-05	0.000481	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—prostate cancer	5.79e-05	0.000481	CcSEcCtD
Afatinib—Dermatitis—Estradiol—prostate cancer	5.79e-05	0.000481	CcSEcCtD
Afatinib—Headache—Estradiol—prostate cancer	5.76e-05	0.000478	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—prostate cancer	5.75e-05	0.000477	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—prostate cancer	5.69e-05	0.000473	CcSEcCtD
Afatinib—Infection—Capecitabine—prostate cancer	5.69e-05	0.000473	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—prostate cancer	5.65e-05	0.000469	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—prostate cancer	5.63e-05	0.000468	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—prostate cancer	5.63e-05	0.000468	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—prostate cancer	5.63e-05	0.000468	CcSEcCtD
Afatinib—Nervous system disorder—Capecitabine—prostate cancer	5.62e-05	0.000467	CcSEcCtD
Afatinib—Gefitinib—CYP3A4—prostate cancer	5.59e-05	0.011	CrCbGaD
Afatinib—Skin disorder—Capecitabine—prostate cancer	5.57e-05	0.000462	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—prostate cancer	5.55e-05	0.000461	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—prostate cancer	5.52e-05	0.000459	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—prostate cancer	5.51e-05	0.000457	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—prostate cancer	5.48e-05	0.000455	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—prostate cancer	5.46e-05	0.000454	CcSEcCtD
Afatinib—Nausea—Estradiol—prostate cancer	5.46e-05	0.000453	CcSEcCtD
Afatinib—Vomiting—Mitoxantrone—prostate cancer	5.44e-05	0.000452	CcSEcCtD
Afatinib—Rash—Mitoxantrone—prostate cancer	5.4e-05	0.000448	CcSEcCtD
Afatinib—Dermatitis—Mitoxantrone—prostate cancer	5.39e-05	0.000448	CcSEcCtD
Afatinib—Headache—Mitoxantrone—prostate cancer	5.36e-05	0.000445	CcSEcCtD
Afatinib—Insomnia—Docetaxel—prostate cancer	5.35e-05	0.000445	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.29e-05	0.000439	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—prostate cancer	5.28e-05	0.000438	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—prostate cancer	5.25e-05	0.000436	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—prostate cancer	5.21e-05	0.000433	CcSEcCtD
Afatinib—ERBB2—Triamcinolone—Prednisone—prostate cancer	5.2e-05	0.0165	CbGdCrCtD
Afatinib—Insomnia—Capecitabine—prostate cancer	5.18e-05	0.00043	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—prostate cancer	5.15e-05	0.000427	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—prostate cancer	5.13e-05	0.000426	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—prostate cancer	5.11e-05	0.000424	CcSEcCtD
Afatinib—Asthenia—Etoposide—prostate cancer	5.11e-05	0.000424	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—prostate cancer	5.11e-05	0.000424	CcSEcCtD
Afatinib—Dyspnoea—Capecitabine—prostate cancer	5.11e-05	0.000424	CcSEcCtD
Afatinib—Fatigue—Docetaxel—prostate cancer	5.1e-05	0.000424	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—prostate cancer	5.1e-05	0.000423	CcSEcCtD
Afatinib—Nausea—Mitoxantrone—prostate cancer	5.09e-05	0.000422	CcSEcCtD
Afatinib—Infection—Prednisone—prostate cancer	5.07e-05	0.000421	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—prostate cancer	5.06e-05	0.000421	CcSEcCtD
Afatinib—Constipation—Docetaxel—prostate cancer	5.06e-05	0.00042	CcSEcCtD
Afatinib—Dyspepsia—Capecitabine—prostate cancer	5.04e-05	0.000419	CcSEcCtD
Afatinib—Pruritus—Etoposide—prostate cancer	5.04e-05	0.000418	CcSEcCtD
Afatinib—Nervous system disorder—Prednisone—prostate cancer	5.01e-05	0.000416	CcSEcCtD
Afatinib—Decreased appetite—Capecitabine—prostate cancer	4.98e-05	0.000414	CcSEcCtD
Afatinib—Alopecia—Epirubicin—prostate cancer	4.97e-05	0.000412	CcSEcCtD
Afatinib—Skin disorder—Prednisone—prostate cancer	4.96e-05	0.000412	CcSEcCtD
Afatinib—Gastrointestinal disorder—Capecitabine—prostate cancer	4.95e-05	0.000411	CcSEcCtD
Afatinib—Fatigue—Capecitabine—prostate cancer	4.94e-05	0.00041	CcSEcCtD
Afatinib—ERBB2—Desoximetasone—Prednisone—prostate cancer	4.93e-05	0.0156	CbGdCrCtD
Afatinib—Mental disorder—Epirubicin—prostate cancer	4.92e-05	0.000409	CcSEcCtD
Afatinib—Constipation—Capecitabine—prostate cancer	4.9e-05	0.000407	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—prostate cancer	4.89e-05	0.000406	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—prostate cancer	4.87e-05	0.000405	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—prostate cancer	4.86e-05	0.000404	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—prostate cancer	4.79e-05	0.000398	CcSEcCtD
Afatinib—Back pain—Epirubicin—prostate cancer	4.73e-05	0.000393	CcSEcCtD
Afatinib—Dizziness—Etoposide—prostate cancer	4.71e-05	0.000391	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—prostate cancer	4.7e-05	0.000391	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—prostate cancer	4.69e-05	0.000389	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—prostate cancer	4.68e-05	0.000389	CcSEcCtD
Afatinib—Insomnia—Prednisone—prostate cancer	4.62e-05	0.000383	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—prostate cancer	4.59e-05	0.000382	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—prostate cancer	4.55e-05	0.000378	CcSEcCtD
Afatinib—Body temperature increased—Capecitabine—prostate cancer	4.53e-05	0.000376	CcSEcCtD
Afatinib—Vomiting—Etoposide—prostate cancer	4.53e-05	0.000376	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—prostate cancer	4.53e-05	0.000376	CcSEcCtD
Afatinib—Dyspepsia—Prednisone—prostate cancer	4.49e-05	0.000373	CcSEcCtD
Afatinib—Rash—Etoposide—prostate cancer	4.49e-05	0.000373	CcSEcCtD
Afatinib—Dermatitis—Etoposide—prostate cancer	4.49e-05	0.000373	CcSEcCtD
Afatinib—Headache—Etoposide—prostate cancer	4.46e-05	0.000371	CcSEcCtD
Afatinib—Decreased appetite—Prednisone—prostate cancer	4.44e-05	0.000369	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—prostate cancer	4.43e-05	0.000368	CcSEcCtD
Afatinib—Fatigue—Prednisone—prostate cancer	4.4e-05	0.000366	CcSEcCtD
Afatinib—Back pain—Doxorubicin—prostate cancer	4.38e-05	0.000364	CcSEcCtD
Afatinib—Constipation—Prednisone—prostate cancer	4.36e-05	0.000363	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—prostate cancer	4.35e-05	0.000361	CcSEcCtD
Afatinib—Cough—Epirubicin—prostate cancer	4.27e-05	0.000355	CcSEcCtD
Afatinib—Asthenia—Docetaxel—prostate cancer	4.25e-05	0.000353	CcSEcCtD
Afatinib—Nausea—Etoposide—prostate cancer	4.23e-05	0.000351	CcSEcCtD
Afatinib—Pruritus—Docetaxel—prostate cancer	4.19e-05	0.000348	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.14e-05	0.000343	CcSEcCtD
Afatinib—Asthenia—Capecitabine—prostate cancer	4.11e-05	0.000341	CcSEcCtD
Afatinib—Pruritus—Capecitabine—prostate cancer	4.05e-05	0.000337	CcSEcCtD
Afatinib—Diarrhoea—Docetaxel—prostate cancer	4.05e-05	0.000336	CcSEcCtD
Afatinib—Body temperature increased—Prednisone—prostate cancer	4.04e-05	0.000335	CcSEcCtD
Afatinib—Infection—Epirubicin—prostate cancer	3.97e-05	0.000329	CcSEcCtD
Afatinib—Cough—Doxorubicin—prostate cancer	3.95e-05	0.000328	CcSEcCtD
Afatinib—Diarrhoea—Capecitabine—prostate cancer	3.92e-05	0.000326	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—prostate cancer	3.91e-05	0.000325	CcSEcCtD
Afatinib—Dizziness—Docetaxel—prostate cancer	3.91e-05	0.000325	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—prostate cancer	3.88e-05	0.000322	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.83e-05	0.000318	CcSEcCtD
Afatinib—Dizziness—Capecitabine—prostate cancer	3.79e-05	0.000315	CcSEcCtD
Afatinib—Vomiting—Docetaxel—prostate cancer	3.76e-05	0.000313	CcSEcCtD
Afatinib—Rash—Docetaxel—prostate cancer	3.73e-05	0.00031	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—prostate cancer	3.73e-05	0.00031	CcSEcCtD
Afatinib—Headache—Docetaxel—prostate cancer	3.71e-05	0.000308	CcSEcCtD
Afatinib—Infection—Doxorubicin—prostate cancer	3.67e-05	0.000305	CcSEcCtD
Afatinib—Asthenia—Prednisone—prostate cancer	3.66e-05	0.000304	CcSEcCtD
Afatinib—Vomiting—Capecitabine—prostate cancer	3.64e-05	0.000303	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—prostate cancer	3.62e-05	0.000301	CcSEcCtD
Afatinib—Rash—Capecitabine—prostate cancer	3.61e-05	0.0003	CcSEcCtD
Afatinib—Pruritus—Prednisone—prostate cancer	3.61e-05	0.0003	CcSEcCtD
Afatinib—Insomnia—Epirubicin—prostate cancer	3.61e-05	0.0003	CcSEcCtD
Afatinib—Dermatitis—Capecitabine—prostate cancer	3.61e-05	0.0003	CcSEcCtD
Afatinib—Headache—Capecitabine—prostate cancer	3.59e-05	0.000298	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—prostate cancer	3.59e-05	0.000298	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—prostate cancer	3.56e-05	0.000296	CcSEcCtD
Afatinib—Nausea—Docetaxel—prostate cancer	3.52e-05	0.000292	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—prostate cancer	3.51e-05	0.000292	CcSEcCtD
Afatinib—Diarrhoea—Prednisone—prostate cancer	3.49e-05	0.00029	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—prostate cancer	3.47e-05	0.000288	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—prostate cancer	3.45e-05	0.000286	CcSEcCtD
Afatinib—Fatigue—Epirubicin—prostate cancer	3.44e-05	0.000286	CcSEcCtD
Afatinib—Constipation—Epirubicin—prostate cancer	3.41e-05	0.000284	CcSEcCtD
Afatinib—Nausea—Capecitabine—prostate cancer	3.4e-05	0.000283	CcSEcCtD
Afatinib—Dizziness—Prednisone—prostate cancer	3.38e-05	0.00028	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—prostate cancer	3.34e-05	0.000277	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—prostate cancer	3.29e-05	0.000274	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—prostate cancer	3.25e-05	0.00027	CcSEcCtD
Afatinib—Vomiting—Prednisone—prostate cancer	3.25e-05	0.00027	CcSEcCtD
Afatinib—Rash—Prednisone—prostate cancer	3.22e-05	0.000267	CcSEcCtD
Afatinib—Dermatitis—Prednisone—prostate cancer	3.22e-05	0.000267	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—prostate cancer	3.21e-05	0.000267	CcSEcCtD
Afatinib—Headache—Prednisone—prostate cancer	3.2e-05	0.000266	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.19e-05	0.000265	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—prostate cancer	3.18e-05	0.000265	CcSEcCtD
Afatinib—Constipation—Doxorubicin—prostate cancer	3.16e-05	0.000262	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—prostate cancer	3.16e-05	0.000262	CcSEcCtD
Afatinib—Nausea—Prednisone—prostate cancer	3.03e-05	0.000252	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—prostate cancer	2.92e-05	0.000243	CcSEcCtD
Afatinib—Asthenia—Epirubicin—prostate cancer	2.86e-05	0.000238	CcSEcCtD
Afatinib—Pruritus—Epirubicin—prostate cancer	2.82e-05	0.000235	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—prostate cancer	2.73e-05	0.000227	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—prostate cancer	2.65e-05	0.00022	CcSEcCtD
Afatinib—Dizziness—Epirubicin—prostate cancer	2.64e-05	0.000219	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—prostate cancer	2.61e-05	0.000217	CcSEcCtD
Afatinib—Vomiting—Epirubicin—prostate cancer	2.54e-05	0.000211	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—prostate cancer	2.53e-05	0.00021	CcSEcCtD
Afatinib—Rash—Epirubicin—prostate cancer	2.52e-05	0.000209	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—prostate cancer	2.51e-05	0.000209	CcSEcCtD
Afatinib—Headache—Epirubicin—prostate cancer	2.5e-05	0.000208	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—prostate cancer	2.44e-05	0.000203	CcSEcCtD
Afatinib—Nausea—Epirubicin—prostate cancer	2.37e-05	0.000197	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—prostate cancer	2.35e-05	0.000195	CcSEcCtD
Afatinib—Rash—Doxorubicin—prostate cancer	2.33e-05	0.000193	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—prostate cancer	2.33e-05	0.000193	CcSEcCtD
Afatinib—Headache—Doxorubicin—prostate cancer	2.31e-05	0.000192	CcSEcCtD
Afatinib—Nausea—Doxorubicin—prostate cancer	2.19e-05	0.000182	CcSEcCtD
Afatinib—ERBB2—Signaling Pathways—TGFB1—prostate cancer	1.52e-06	1.1e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HIF1A—prostate cancer	1.52e-06	1.1e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—prostate cancer	1.51e-06	1.09e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MDM2—prostate cancer	1.51e-06	1.09e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—prostate cancer	1.5e-06	1.09e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—prostate cancer	1.5e-06	1.08e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—prostate cancer	1.5e-06	1.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—prostate cancer	1.49e-06	1.08e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1B—prostate cancer	1.49e-06	1.08e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—SRC—prostate cancer	1.49e-06	1.08e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—prostate cancer	1.49e-06	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Disease—JAK2—prostate cancer	1.49e-06	1.08e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—prostate cancer	1.49e-06	1.07e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LEP—prostate cancer	1.49e-06	1.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—prostate cancer	1.48e-06	1.07e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC5A5—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CAV1—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HIF1A—prostate cancer	1.47e-06	1.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—prostate cancer	1.46e-06	1.05e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—prostate cancer	1.46e-06	1.05e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—prostate cancer	1.46e-06	1.05e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—prostate cancer	1.45e-06	1.05e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MDM2—prostate cancer	1.45e-06	1.05e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—prostate cancer	1.45e-06	1.05e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1B—prostate cancer	1.44e-06	1.04e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2E1—prostate cancer	1.44e-06	1.04e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—prostate cancer	1.44e-06	1.04e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1B—prostate cancer	1.44e-06	1.04e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—prostate cancer	1.43e-06	1.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LEP—prostate cancer	1.43e-06	1.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NQO1—prostate cancer	1.42e-06	1.03e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—prostate cancer	1.42e-06	1.03e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CAV1—prostate cancer	1.42e-06	1.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—prostate cancer	1.42e-06	1.02e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—INS—prostate cancer	1.42e-06	1.02e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—prostate cancer	1.41e-06	1.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—prostate cancer	1.41e-06	1.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—prostate cancer	1.41e-06	1.02e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—prostate cancer	1.41e-06	1.02e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—prostate cancer	1.41e-06	1.02e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—prostate cancer	1.41e-06	1.02e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—prostate cancer	1.4e-06	1.01e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TH—prostate cancer	1.4e-06	1.01e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—prostate cancer	1.4e-06	1.01e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—prostate cancer	1.39e-06	1e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CREBBP—prostate cancer	1.39e-06	1e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP3A4—prostate cancer	1.39e-06	1e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BAD—prostate cancer	1.39e-06	1e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—prostate cancer	1.38e-06	9.95e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—prostate cancer	1.38e-06	9.94e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—prostate cancer	1.38e-06	9.94e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—prostate cancer	1.37e-06	9.92e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—prostate cancer	1.37e-06	9.88e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1B1—prostate cancer	1.36e-06	9.85e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—prostate cancer	1.36e-06	9.84e-06	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—prostate cancer	1.36e-06	9.82e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—prostate cancer	1.36e-06	9.81e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—prostate cancer	1.34e-06	9.69e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—prostate cancer	1.34e-06	9.69e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—prostate cancer	1.34e-06	9.65e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BAD—prostate cancer	1.33e-06	9.64e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—prostate cancer	1.33e-06	9.61e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—prostate cancer	1.33e-06	9.59e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—prostate cancer	1.33e-06	9.59e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—prostate cancer	1.33e-06	9.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EGF—prostate cancer	1.33e-06	9.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS1—prostate cancer	1.33e-06	9.58e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—prostate cancer	1.32e-06	9.56e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GGT1—prostate cancer	1.32e-06	9.54e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—prostate cancer	1.32e-06	9.51e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—EP300—prostate cancer	1.31e-06	9.46e-06	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—prostate cancer	1.31e-06	9.46e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—prostate cancer	1.31e-06	9.44e-06	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—prostate cancer	1.31e-06	9.43e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—prostate cancer	1.3e-06	9.4e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NCOA1—prostate cancer	1.3e-06	9.4e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—prostate cancer	1.3e-06	9.36e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—prostate cancer	1.29e-06	9.34e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—prostate cancer	1.29e-06	9.34e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GSK3B—prostate cancer	1.29e-06	9.3e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—prostate cancer	1.28e-06	9.27e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP19A1—prostate cancer	1.28e-06	9.26e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGF—prostate cancer	1.28e-06	9.23e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS1—prostate cancer	1.28e-06	9.23e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—prostate cancer	1.28e-06	9.22e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—prostate cancer	1.27e-06	9.2e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—prostate cancer	1.27e-06	9.18e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—INS—prostate cancer	1.27e-06	9.17e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—prostate cancer	1.27e-06	9.16e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EP300—prostate cancer	1.27e-06	9.15e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—EP300—prostate cancer	1.26e-06	9.12e-06	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—prostate cancer	1.26e-06	9.08e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—prostate cancer	1.25e-06	9.06e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—prostate cancer	1.25e-06	9.06e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CREBBP—prostate cancer	1.24e-06	8.98e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—prostate cancer	1.24e-06	8.98e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GSK3B—prostate cancer	1.24e-06	8.96e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—RXRA—prostate cancer	1.24e-06	8.94e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—prostate cancer	1.24e-06	8.92e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—prostate cancer	1.23e-06	8.92e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—prostate cancer	1.23e-06	8.9e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—prostate cancer	1.23e-06	8.87e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—prostate cancer	1.23e-06	8.87e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—prostate cancer	1.23e-06	8.87e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—prostate cancer	1.23e-06	8.85e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—INS—prostate cancer	1.22e-06	8.84e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—prostate cancer	1.22e-06	8.83e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—EP300—prostate cancer	1.21e-06	8.74e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—prostate cancer	1.2e-06	8.66e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CREBBP—prostate cancer	1.2e-06	8.66e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—COMT—prostate cancer	1.19e-06	8.61e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—prostate cancer	1.19e-06	8.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAP2K1—prostate cancer	1.19e-06	8.57e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—prostate cancer	1.19e-06	8.57e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—prostate cancer	1.18e-06	8.55e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—prostate cancer	1.18e-06	8.55e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—prostate cancer	1.18e-06	8.55e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—prostate cancer	1.18e-06	8.52e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—prostate cancer	1.18e-06	8.49e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ITPR1—prostate cancer	1.17e-06	8.43e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SERPINE1—prostate cancer	1.17e-06	8.42e-06	CbGpPWpGaD
Afatinib—LCK—Disease—EP300—prostate cancer	1.17e-06	8.42e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—prostate cancer	1.15e-06	8.34e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—prostate cancer	1.15e-06	8.29e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—prostate cancer	1.15e-06	8.29e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAP2K1—prostate cancer	1.14e-06	8.26e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—prostate cancer	1.14e-06	8.21e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—prostate cancer	1.14e-06	8.21e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—prostate cancer	1.13e-06	8.19e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—prostate cancer	1.13e-06	8.19e-06	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—prostate cancer	1.13e-06	8.19e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—prostate cancer	1.13e-06	8.16e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGF2—prostate cancer	1.13e-06	8.15e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SERPINE1—prostate cancer	1.12e-06	8.12e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—prostate cancer	1.11e-06	8.04e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—prostate cancer	1.1e-06	7.97e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMS—prostate cancer	1.1e-06	7.97e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—prostate cancer	1.1e-06	7.95e-06	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—prostate cancer	1.09e-06	7.89e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—prostate cancer	1.09e-06	7.88e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGF2—prostate cancer	1.09e-06	7.86e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JAK2—prostate cancer	1.08e-06	7.82e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—prostate cancer	1.08e-06	7.8e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—prostate cancer	1.08e-06	7.77e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—prostate cancer	1.07e-06	7.75e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—LPL—prostate cancer	1.07e-06	7.73e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—prostate cancer	1.06e-06	7.66e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—prostate cancer	1.06e-06	7.65e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—prostate cancer	1.06e-06	7.63e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—prostate cancer	1.05e-06	7.62e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—prostate cancer	1.05e-06	7.61e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—prostate cancer	1.05e-06	7.59e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—prostate cancer	1.04e-06	7.53e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JAK2—prostate cancer	1.04e-06	7.53e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—prostate cancer	1.04e-06	7.52e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1A1—prostate cancer	1.03e-06	7.47e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—prostate cancer	1.03e-06	7.42e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ERCC2—prostate cancer	1.03e-06	7.4e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—prostate cancer	1.02e-06	7.37e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—prostate cancer	1.02e-06	7.35e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—prostate cancer	1.02e-06	7.34e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—prostate cancer	1.02e-06	7.34e-06	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—prostate cancer	1.01e-06	7.32e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—prostate cancer	1e-06	7.25e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—prostate cancer	1e-06	7.25e-06	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—prostate cancer	9.94e-07	7.18e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—prostate cancer	9.92e-07	7.16e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—prostate cancer	9.91e-07	7.15e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—prostate cancer	9.88e-07	7.13e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—prostate cancer	9.74e-07	7.03e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—prostate cancer	9.69e-07	7e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—prostate cancer	9.65e-07	6.97e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—prostate cancer	9.64e-07	6.96e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—prostate cancer	9.52e-07	6.87e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—EP300—prostate cancer	9.46e-07	6.83e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARA—prostate cancer	9.45e-07	6.83e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—prostate cancer	9.45e-07	6.83e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—prostate cancer	9.44e-07	6.82e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—prostate cancer	9.39e-07	6.78e-06	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—prostate cancer	9.39e-07	6.78e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—prostate cancer	9.37e-07	6.77e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—prostate cancer	9.34e-07	6.74e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—prostate cancer	9.3e-07	6.71e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—prostate cancer	9.26e-07	6.69e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—prostate cancer	9.2e-07	6.65e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—prostate cancer	9.11e-07	6.58e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—prostate cancer	9.11e-07	6.58e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—prostate cancer	9.1e-07	6.57e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—prostate cancer	9.07e-07	6.55e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—prostate cancer	8.95e-07	6.46e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—prostate cancer	8.93e-07	6.45e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—prostate cancer	8.9e-07	6.43e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAV1—prostate cancer	8.89e-07	6.42e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—prostate cancer	8.88e-07	6.41e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—prostate cancer	8.87e-07	6.4e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—prostate cancer	8.78e-07	6.34e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—prostate cancer	8.66e-07	6.26e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—prostate cancer	8.62e-07	6.23e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—prostate cancer	8.61e-07	6.22e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—prostate cancer	8.58e-07	6.2e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—prostate cancer	8.58e-07	6.2e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—prostate cancer	8.56e-07	6.18e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EP300—prostate cancer	8.47e-07	6.12e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—prostate cancer	8.3e-07	5.99e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—prostate cancer	8.27e-07	5.97e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—prostate cancer	8.24e-07	5.95e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EP300—prostate cancer	8.16e-07	5.9e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—prostate cancer	8.1e-07	5.85e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—prostate cancer	8.02e-07	5.79e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—prostate cancer	7.94e-07	5.74e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—prostate cancer	7.94e-07	5.73e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—prostate cancer	7.92e-07	5.72e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—prostate cancer	7.92e-07	5.72e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—prostate cancer	7.73e-07	5.58e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—INS—prostate cancer	7.66e-07	5.54e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—prostate cancer	7.65e-07	5.53e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—prostate cancer	7.65e-07	5.53e-06	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—prostate cancer	7.64e-07	5.51e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—prostate cancer	7.63e-07	5.51e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CREBBP—prostate cancer	7.51e-07	5.42e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—prostate cancer	7.38e-07	5.33e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—prostate cancer	7.36e-07	5.32e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—prostate cancer	7.31e-07	5.28e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—prostate cancer	7.12e-07	5.14e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—prostate cancer	7.11e-07	5.14e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—prostate cancer	7.1e-07	5.12e-06	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—prostate cancer	7.04e-07	5.09e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—prostate cancer	7e-07	5.05e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—prostate cancer	6.96e-07	5.02e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—prostate cancer	6.82e-07	4.93e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—prostate cancer	6.72e-07	4.85e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—prostate cancer	6.57e-07	4.75e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—prostate cancer	6.27e-07	4.53e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—prostate cancer	6.2e-07	4.48e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—prostate cancer	6.15e-07	4.44e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—prostate cancer	6.06e-07	4.38e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—prostate cancer	6.04e-07	4.36e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—prostate cancer	5.84e-07	4.22e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—prostate cancer	5.71e-07	4.13e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—prostate cancer	5.55e-07	4.01e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—prostate cancer	5.36e-07	3.87e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—prostate cancer	5.35e-07	3.86e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—prostate cancer	5.12e-07	3.7e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—EP300—prostate cancer	5.11e-07	3.69e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—prostate cancer	4.93e-07	3.56e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—prostate cancer	3.78e-07	2.73e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—prostate cancer	3.09e-07	2.23e-06	CbGpPWpGaD
